Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

dapagliflozin Articles

AstraZeneca and Bristol-Myers get first approval for diabetes drug Forxiga

15 November 2012

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021

16 October 2012

FDA’s CRL on dapagliflozin calls for more clinical data

19 January 2012

AstraZeneca and B-MS see delay for dapagliflozin, as AZ posts 3rd-qtr 2011 results with generics taking a toll

27 October 2011

Russia’s type 2 diabetes drug market will grow to $1.7 billion in 2015

13 October 2011

US FDA advisory gives thumbs down to B-MS and AstraZeneca diabetes drug dapagliflozin on safety issues

20 July 2011

US FDA warns of bladder and breast cancer risk for Bristol-Myers/AstraZeneca diabetes drug dapagliflozin ahead of advisory

18 July 2011

Highlights from American Diabetes Association meeting

27 June 2011

AstraZeneca/Bristol-Myers diabetes drug dapagliflozin NDA accepted by US FDA

9 March 2011

Bristol-Myers Squibb’s R&D pipeline boosted by diabetes drug dapagliflozin, say Zacks analysts

18 October 2010

AstraZeneca/Bristol-Myers dapagliflozin shows positive results in Ph III trial

26 September 2010

Positive new data on diabetes drugs from Novo Nordisk, AstraZeneca/B-MS and Sanofi-Aventis presented at EASD meeting

21 September 2010

Highlights of ADA meeting see good results for canagliflozin, Victoza, dapagliflozin, Lantus & Apidra and taspoglutide

28 June 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Negative US patent ruling for Novo Nordisk on Prandin
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Negative US patent ruling for Novo Nordisk on Prandin
  • Daiichi Sankyo files for Japanese approval of Prasugrel
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS